Global Nivolumab Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Nivolumab Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
OPDIVO® (nivolumab) is a prescription medication that treats certain types of cancer.
Nivolumab Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Nivolumab Drugs market is projected to reach US$ 15620 million in 2029, increasing from US$ 9567 million in 2022, with the CAGR of 6.8% during the period of 2024 to 2029. Demand from Retail Pharmacy and Hospital Pharmacy are the major drivers for the industry.
The OPDIVO market is primarily driven by the growing demand for innovative immunotherapy treatments in the field of oncology. OPDIVO (nivolumab) is a checkpoint inhibitor that harnesses the immune system to fight cancer cells by blocking certain proteins that suppress the immune response. The increasing prevalence of cancer cases, coupled with the need for targeted therapies that offer improved survival rates and fewer adverse effects compared to traditional treatments, contributes to market growth. Moreover, the expanding range of approved indications for OPDIVO, including advanced melanoma, lung cancer, and other malignancies, further propels adoption. However, challenges include managing potential immune-related adverse events and addressing variations in patient responses to immunotherapy. Navigating the competitive landscape in the immunotherapy market and ensuring affordability and access to these treatments for a broader patient population pose ongoing concerns. The market's success hinges on continuous research to identify optimal treatment combinations and patient profiles for OPDIVO, comprehensive patient education about potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and research institutions to optimize cancer treatment while addressing the evolving challenges associated with OPDIVO therapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Nivolumab Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bristol-Myers Squibb
Ono Pharmaceutical
Segment by Type
10ml
4ml
24ml
Retail Pharmacy
Hospital Pharmacy
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Nivolumab Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Nivolumab Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Nivolumab Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Nivolumab Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Nivolumab Drugs introduction, etc. Nivolumab Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Nivolumab Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Nivolumab Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Nivolumab Drugs market is projected to reach US$ 15620 million in 2029, increasing from US$ 9567 million in 2022, with the CAGR of 6.8% during the period of 2024 to 2029. Demand from Retail Pharmacy and Hospital Pharmacy are the major drivers for the industry.
The OPDIVO market is primarily driven by the growing demand for innovative immunotherapy treatments in the field of oncology. OPDIVO (nivolumab) is a checkpoint inhibitor that harnesses the immune system to fight cancer cells by blocking certain proteins that suppress the immune response. The increasing prevalence of cancer cases, coupled with the need for targeted therapies that offer improved survival rates and fewer adverse effects compared to traditional treatments, contributes to market growth. Moreover, the expanding range of approved indications for OPDIVO, including advanced melanoma, lung cancer, and other malignancies, further propels adoption. However, challenges include managing potential immune-related adverse events and addressing variations in patient responses to immunotherapy. Navigating the competitive landscape in the immunotherapy market and ensuring affordability and access to these treatments for a broader patient population pose ongoing concerns. The market's success hinges on continuous research to identify optimal treatment combinations and patient profiles for OPDIVO, comprehensive patient education about potential benefits and risks, and collaborations between pharmaceutical companies, healthcare providers, and research institutions to optimize cancer treatment while addressing the evolving challenges associated with OPDIVO therapy.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Nivolumab Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bristol-Myers Squibb
Ono Pharmaceutical
Segment by Type
10ml
4ml
24ml
Segment by Application
Retail Pharmacy
Hospital Pharmacy
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Nivolumab Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Nivolumab Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Nivolumab Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Nivolumab Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Nivolumab Drugs introduction, etc. Nivolumab Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Nivolumab Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices